Transcript Slide 1

Overview of EMCDDA’s
2009 Scientific Work Programme
Paul Griffiths, Roland Simon - REITOX Meeting, Lisbon, November 2007
Context: Complete the 3-Year-Cyle (1)
•
Last year of the 3 Year work programme 2007/2009
• Commitment to scientific excellence;
• Commitment to partnership;
• Commitment to good governance and efficiency.
•
•
•
•
EU action plan 2009-2012
New Regulation
External evaluation
Enlargement and International cooperation remain important
Context: Complete the 3-Year-Cyle (2)
• Implementation of FONTE
• More efforts invested in analysis and transversal work
• New communication strategy and international cooperation
strategy
• New EU Action Plan
2009 Core activities
• Monitoring and reporting on the drugs phenomenon
• Routine reporting activities
• Expert meetings
• Continue work to identify and disseminate best practices
• Continue the implementation more professional approach to
data management and statistical reporting
Consolidate monitoring – Strategic objectives
• Continue the work on quality assurance:
• Continue the revision of the reporting tools according to the
same principles adopted in 2007
• Strategy for monitoring and reporting on drug treatment
• More sensitivity to polydrug use and PDU
• Improve monitoring of supply issues
Selected activities (1)
• Put into practice minimum implementation standards and criteria
for key indicators.
• Further develop and conceptualise problem drug use and other
intensive, long-term and risky patterns of drug use and improve
estimation techniques.
• Continue efforts to apply new estimation techniques both on PDU
(problem drug use) prevalence and incidence.
• Explore solution for monitoring polydrug use, in particular how to
better exploit the data that is already collected in existing systems.
• Carry out critical review of the treatment demand indicator (TDI).
• Enhance understanding of DRID spread and intervention
effectiveness (through modelling).
Selected activities (2)
• Revise/finalise data-collection instruments and protocols on Social
rehabilitation, Alternatives to prison, Policy and institutional
framework.
• Carry out critical review of existing data collection tools in area of
drug supply
• Continue to develop reporting and analytical capacity on EU drug
legislation and associated activities.
• Increase understanding of mortality related to specific opioids
(substitution drugs, Fentanyl, etc.) and drug combinations.
• Audit of the European Cannabis market
Selected activities (3)
• Carry out the special analyses necessary for 2009 selected issues
(Sentencing statistics, Trends in injecting drug use and Polydrug use
in Europe).
• Conduct joint data analysis from general population surveys
including psychometric scales to measure intensive forms of
cannabis use.
• Identify the prevention needs of the most vulnerable within a
universal programme approach.
• Maintain and further develop the Best practice portal, the EIB
(Evaluation instruments bank) and PERK (Prevention and
evaluation resources kit).
Enhanced analysis of data – Specific Products (1)
EMCDDA Scientific Monograph
• Harm reduction Monograph
EMCDDA Insights
• New groups of psychoactive substances in Europe
• Internet based treatment
EMCDDA Selected Issues
• Sentencing statistics
• Trends in injecting drug use
• Polydrug use in Europe
EMCDDA Manuals
• Guidelines for risk assessment of new psychoactive substances
Drug profiles (GHB, Ketamine, Methadone, Buprenorphine)
Enhanced analysis of data – Specific Products (2)
Drugs in focus – policy briefings
• Europe’s evolving opiate situation – issues for policy and
practice
• Working with the criminal justice setting – a key area for drug
interventions
• Indiciated prevention and neurobiology
Online tools and web-based resources
• Portal for dissemination of best practice
• ELDD and legal topic overviews on
-
Limited quantities of drugs
Drug laws and the internet
• Key indicator portal
• Country situation summary
Enhanced analysis of data – Specific Products (3)
Conference proceedings
• Conference proceedings
• Conference website
• EU drugs legislation in practice (linked publication)
Joint publications and contribution to partners’ reports
• Developing and sustaining a national drugs observatory with CICAD.
• A systematic review of drug surveys and methods used in the EU
Member States - With Institute for Social Drug Research, Ghent
• Vulnerable groups and individuals in youth population –
in collaboration with NIDA
• Contribution to the revision of the Addiction Severity Index –
in collaboration with UNODC
• Handbook of economics of illicit drugs Publication 2010 –
in collaboration with Paul de Grauwe, University Leuwen
Enhanced analysis of data – Specific Products (3)
EMCDDA technical papers and reviews
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
State of implementation of the EMCDDA key epidemiological indicators based on newly defined criteria
Drug-related infectious diseases (DRID) revised protocol
Mortality cohort study revised protocol
Treatment demand indicator (TDI) revised protocol
Report on the first results of the extensive data collection on treatment prevalence
Update on cannabis markets in Europe
Hospital emergency data: conclusion on feasibility (article)
Heroin use incidence estimation: comparison of two methods in five European countries
Review of IDU estimation in EU countries
Modelling hepatitis C trends (articles)
Specific analysis on drug-related infectious diseases/injecting drug use/harm reduction (article)
Review of available data, potential indicators and options for monitoring strategies in the areas of drug supply and
drug supply reduction
Guidelines on collecting retail drug prices Estimates of drug consumption
Treatment prevalence analysis (article)
Gender analysis among treated clients (article)
Working/discussion paper on methodology, sources and issues to assess health consequences of non opiate
substances use
Preliminary results of literature review on epidemiology, risk factors and health impact of non fatal OD
Additional activities
•
•
•
•
Move to the new building
Conduct an international conference
Products linked to the conference
Ongoing: strengthen collaboration with relevant institutional and
scientific partners - in particular
•
•
the Commission,
UNODC
•
EUROPOL
•
Pompidou Group